Skip to content

Rapid identification and development of SARS-CoV-2 selective Optimers

The COVID-19 pandemic has presented significant challenges to the biopharmaceutical industry, requiring rapid discovery and development of affinity reagents targeting SARS-CoV-2 for research, diagnostics and therapeutics. The long development times, batch inconsistencies and high cost-to-manufacture of protein affinity reagents such as antibodies, have been highlighted during this response.

Our new application note details how we utilised our established Optimer selection and development processes to:

  • identify and develop Optimers targeting SARS-CoV-2 proteins in just 17 days.
  • demonstrate superior performance of our Optimer reagents compared to commercially available antibodies and competitor aptamers to the same targets.
  • achieve highly consistent performance across different batches of SARS-CoV-2 specific Optimers.
  • evaluated Optimer performance across multiple analytical platforms.

Download Application Note


Tags

Application NotesCOVID-19SARS-CoV-2

Start your next project with Aptamer Group

Contact one of our experts today